Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial

医学 前列腺癌 临床终点 进行性疾病 放射治疗 泌尿科 SABR波动模型 肿瘤科 临床研究阶段 内科学 阿维鲁单抗 临床试验 外科 癌症 化疗 彭布罗利珠单抗 免疫疗法 经济 金融经济学 波动性(金融) 随机波动
作者
Edmond M. Kwan,Lavinia Spain,A. Antón,Chun Loo Gan,Linda Garrett,Deborah Chang,Elizabeth Liow,Caitlin Bennett,Tiantian Zheng,Jianjun Yu,Chao Dai,Pan Du,Shidong Jia,Heidi Fettke,Claire Abou-Seif,Gargi Kothari,Mark Shaw,Phillip Parente,Carmel Pezaro,Ben Tran
出处
期刊:European Urology [Elsevier BV]
卷期号:81 (3): 253-262 被引量:67
标识
DOI:10.1016/j.eururo.2021.08.011
摘要

Immune checkpoint inhibitor monotherapy in metastatic castration-resistant prostate cancer (mCRPC) has produced modest results. High-dose radiotherapy may be synergistic with checkpoint inhibitors.To evaluate the efficacy and safety of the PD-L1 inhibitor avelumab with stereotactic ablative body radiotherapy (SABR) in mCRPC.From November 2017 to July 2019, this prospective phase 2 study enrolled 31 men with progressive mCRPC after at least one prior androgen receptor-directed therapy. Median follow-up was 18.0 mo.Avelumab 10 mg/kg intravenously every 2 wk for 24 wk (12 cycles). A single fraction of SABR (20 Gy) was administered to one or two disease sites within 5 d before the first and second avelumab treatments.The primary endpoint was the disease control rate (DCR), defined as a confirmed complete or partial response of any duration, or stable disease/non-complete response/non-progressive disease for ≥6 mo (Prostate Cancer Clinical Trials Working Group 3-modified Response Evaluation Criteria in Solid Tumours version 1.1). Secondary endpoints were the objective response rate (ORR), radiographic progression-free survival (rPFS), overall survival (OS), and safety. DCR and ORR were calculated using the Clopper-Pearson exact binomial method.Thirty-one evaluable men were enrolled (median age 71 yr, 71% with ≥2 prior mCRPC therapy lines, 81% with >5 total metastases). The DCR was 48% (15/31; 95% confidence interval [CI] 30-67%) and ORR was 31% (five of 16; 95% CI 11-59%). The ORR in nonirradiated lesions was 33% (four of 12; 95% CI 10-65%). Median rPFS was 8.4 mo (95% CI 4.5-not reached [NR]) and median OS was 14.1 mo (95% CI 8.9-NR). Grade 3-4 treatment-related adverse events occurred in six patients (16%), with three (10%) requiring high-dose corticosteroid therapy. Plasma androgen receptor alterations were associated with lower DCR (22% vs 71%, p = 0.13; Fisher's exact test). Limitations include the small sample size and the absence of a control arm.Avelumab with SABR demonstrated encouraging activity and acceptable toxicity in treatment-refractory mCRPC. This combination warrants further investigation.In this study of men with advanced and heavily pretreated prostate cancer, combining stereotactic radiotherapy with avelumab immunotherapy was safe and resulted in nearly half of patients experiencing cancer control for 6 months or longer. Stereotactic radiotherapy may potentially improve the effectiveness of immunotherapy in prostate cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
鹏liu完成签到,获得积分10
2秒前
活力以冬完成签到,获得积分10
4秒前
开朗含海完成签到,获得积分10
4秒前
Heby完成签到 ,获得积分10
7秒前
amiee发布了新的文献求助10
10秒前
酷炫蛋挞完成签到 ,获得积分10
12秒前
tough_cookie完成签到 ,获得积分10
12秒前
求知小生完成签到 ,获得积分10
13秒前
16秒前
前方的菜鸟完成签到 ,获得积分10
16秒前
花花子完成签到 ,获得积分10
17秒前
syvshc的应助被科研通管家采纳,获得10
18秒前
cssc完成签到,获得积分10
18秒前
arniu2008的应助被科研通管家采纳,获得20
18秒前
Owen的应助被科研通管家采纳,获得10
18秒前
懒猫完成签到,获得积分10
18秒前
鹏liu发布了新的文献求助10
21秒前
凌泉完成签到 ,获得积分10
22秒前
英姑的应助被shally采纳,获得10
25秒前
31秒前
淡然雅彤完成签到,获得积分10
33秒前
画龙点睛完成签到 ,获得积分10
34秒前
shally发布了新的文献求助10
36秒前
虚幻烤鸡完成签到,获得积分10
57秒前
梦瑶完成签到 ,获得积分10
57秒前
ziqizhou完成签到 ,获得积分10
59秒前
Firewoods完成签到 ,获得积分10
1分钟前
科研人完成签到 ,获得积分10
1分钟前
Kevin发布了新的文献求助200
1分钟前
如意的晓槐完成签到 ,获得积分10
1分钟前
内向小霜完成签到 ,获得积分10
1分钟前
烟花的应助被shally采纳,获得10
1分钟前
1分钟前
lllll完成签到 ,获得积分10
1分钟前
1分钟前
范yx发布了新的文献求助10
1分钟前
Eric完成签到,获得积分10
1分钟前
陈烨完成签到,获得积分10
1分钟前
侯子完成签到 ,获得积分10
1分钟前
shally发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185502
求助须知:如何正确求助?哪些是违规求助? 9574220
关于积分的说明 21834553
捐赠科研通 7783121
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558949
邀请新用户注册赠送积分活动 2481357